[Oral antidiabetic monotherapy and combination treatment with glybenclamide (HB 419) and biguanides of insulin receiving diabetics of the adult type].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D001645:Biguanides / Q000008:administration & dosage*; D001786:Blood Glucose / Q000032:analysis; D003510:Cyclohexanes / Q000008:administration & dosage; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D004357:Drug Synergism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D008875:Middle Aged; D013450:Sulfones / Q000008:administration & dosage; D013997:Time Factors; D014508:Urea / Q000008:administration & dosage*
D001645:Biguanides; D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D013450:Sulfones; D014508:Urea
Orale antidiabetische Mono- und Kombinationstherapie mit Glybenclamid (HB 419) und Biguanden bei insulinierten Diabetikern des Erwachsenentyps.